Compare · CBLL vs SLNO
CBLL vs SLNO
Side-by-side comparison of CeriBell Inc. (CBLL) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 2.6x CBLL ($1.06B).
- CBLL has hit the wire 2 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Soleno Therapeutics Inc.
- Price
- $25.05-9.40%
- $53.02+0.08%
- Market cap
- $1.06B
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2014
- News (4w)
- 2
- 0
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest CBLL
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
- President and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott sold $21,150 worth of shares (846 units at $25.00) as part of a pre-agreed trading plan and exercised 846 shares at a strike of $9.41 (SEC Form 4)
- Senior VP, Finance and PAO Foehr David sold $224,451 worth of shares (9,255 units at $24.25) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $4.70, decreasing direct ownership by 5% to 34,144 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 13,276 shares at a strike of $2.76 and sold $118,901 worth of shares (4,887 units at $24.33) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 203,118 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $973,079 worth of shares (39,540 units at $24.61) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 767,191 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott exercised 652 shares at a strike of $9.41 and sold $16,300 worth of shares (652 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)